Orexigen wows analysts with IIb obesity data – FierceBiotech30 Sep
A brilliant move from local biotech Orexigen – combine an existing obesity drug candidate with an antidepressant for a potential blockbuster coctail. Patients in this IIb (mid-late) stage trial lost a whopping 9.9% of body weight during the 24 week period, averaging 22 pounds. And I’ll bet they had fun doing it too!
http://www.fiercebiotech.com/story/orexigen-wows-analysts-iib-obesity-data/2009-09-30?utm_medium=nl&utm_source=internal